Theme |
Gastroenteropancreatic Neuroendocrine Tumors |
Title |
Chemotherapy for Neuroendocrine Neoplasms : Cytotoxic and Molecular-Targeted Therapies |
Author |
Hideyuki Hayashi |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
Author |
Chigusa Morizane |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
Author |
Yasunari Sakamoto |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
Author |
Shunsuke Kondo |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
Author |
HHideki Ueno |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
Author |
Takuji Okusaka |
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
[ Summary ] |
Neuroendocrine neoplasms are rare diseases with limited treatment options available to date, making their treatment extremely difficult. Neuroendocrine neoplasms can be classified into two categories:neuroendocrine tumors (NET) G1/G2, or neuroendocrine carcinoma (NEC). For treatment of NEC, combination chemotherapy regimens consisting of cisplatin and etoposide, or cisplatin and irinotecan (which is a conventional treatment for small cell lung carcinoma) have been widely applied. For treatment of NET G1/G2, large prospective, randomized controlled trials have confirmed the efficacy of new drugs, such as sunitinib and everolimus. Interest in the treatment of NET G1/G2 using these new drugs is increasing. |